There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.
There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.
J Clin Oncol. 2018 Sep 06;:JCO2018793166
Authors: Velho PI, Eisenberger MA
PMID: 30188787 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Velho PI, Eisenberger MA Tags: J Clin Oncol Source Type: research